Cevian Capital II GP Limited increased its total voting rights in medical technology firm Smith & Nephew plc to 14.21%. This represents a rise from the 14.01% stake reported on July 24, 2026.
The firm submitted the regulatory filing for the additional shares on August 11, 2026. Two entities hold the combined stake: Cevian Capital II Master Fund L.P. and Cevian Capital II Co-Investment – Series P L.P.
The acquisition did not trigger a new mandatory notification threshold. Investors are monitoring the accumulation for signs of activist engagement regarding the company's strategic direction.